Immuneering (IMRX) Receivables (2020 - 2023)

Immuneering's Receivables history runs 4 years deep, the most recent figure standing at $1046.0 for Q1 2023.

• On a quarterly basis, Receivables fell 99.63% year-over-year to $1046.0 in Q1 2023; TTM through Mar 2023 was $1046.0, a 99.63% decrease from a year earlier, with the FY2022 full-year figure at $12417.0, down 94.95% from the prior year.
• Receivables eased to $1046.0 in Q1 2023 per IMRX's latest filing, from $12417.0 in the prior quarter.
• Across five years, Receivables topped out at $500110.0 in Q4 2020 and bottomed at $1046.0 in Q1 2023.
• The 4-year median for Receivables is $246040.0 (2021), against an average of $250479.1.
• Across the five-year window, Receivables tumbled 50.8% in 2021 and sank 99.63% in 2023, its largest moves.
• Year by year, Receivables stood at $500110.0 in 2020, then tumbled by 50.8% to $246040.0 in 2021, then plunged by 94.95% to $12417.0 in 2022, then sank by 91.58% to $1046.0 in 2023.
• Per Business Quant, the three latest IMRX Receivables figures stand at $1046.0 (Q1 2023), $12417.0 (Q4 2022), and $70180.0 (Q3 2022).